Fulvestrant - a novel endocrine therapy for breast cancer.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Current Medicinal Chemistry

• Publication date

  2010-03-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/092986710790820633PMID 20156170
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Breast Cancer in Men

  2017cited by this paper
• Bone turnover markers in postmenopausal breast cancer treated with fulvestrant--a pilot study.

  2009cited by this paper
• Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

  2009cited by this paper
• CONFIRM: A Phase III, Randomized, Parallel-Group Trial Comparing Fulvestrant 250 mg vs Fulvestrant 500 mg in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer.

  2009cited by this paper
• Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

  2008cited by this paper
• Fulvestrant (Faslodex) -- how to make a good drug better.

  2007cited by this paper
• Endocrine therapy for breast cancer: an overview.

  2007cited by this paper
• Fulvestrant in Advanced Male Breast Cancer

  2006cited by this paper
• Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.

  2006cited by this paper
• Bone turnover markers in postmenopausal breast cancer patients treated with fulvestrant

  2006cited by this paper
• Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.

  2004cited by this paper
• Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer

  2004cited by this paper
• Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.

  2003cited by this paper
• Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women

  2003cited by this paper
• A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers

  2002cited by this paper
• Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.

  2002cited by this paper
• An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane

  2002cited by this paper
• Breast Cancer in Men

  2002cited by this paper
• Fulvestrant

  2002cited by this paper
• Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.

  2001cited by this paper
• Comparison of the Short-Term Biological Effects of 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17β-diol (Faslodex) versus Tamoxifen in Postmenopausal Women with Primary Breast Cancer

  2001cited by this paper
• Nodal metastasis is highly consistent in squamous cell carcinoma of the vulva.

  2001cited by this paper
• Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.

  2000cited by this paper
• Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group.

  1999cited by this paper
• Multicenter, Phase II Trial of Exemestane as Third-Line Hormonal Therapy of Postmenopausal Women With Metastatic Breast Cancer

  1999cited by this paper
• Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

  1998cited by this paper
• Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen resistant breast cancer

  1997cited by this paper
• Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer

  1997cited by this paper
• Selective inhibition of estrogen-regulated gene expression in vivo by the pure antiestrogen ICI 182,780.

  1997cited by this paper
• Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

  1995cited by this paper
• Contrasting effects of tamoxifen and ICI 182 780 on estrogen-induced calbindin-D 9k gene expression in the uterus and in primary culture of myometrial cells.

  1995cited by this paper
• Gynecologic effects of tamoxifen and the association with endometrial carcinoma

  1995cited by this paper
• Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper
• Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper
• Risk of endometrial cancer after tamoxifen treatment of breast cancer.

  1994cited by this paper
• Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment.

  1994cited by this paper
• The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling.

  1993cited by this paper
• Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780.

  1993cited by this paper
• Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover.

  1992cited by this paper
• ICI 182,780, a new antioestrogen with clinical potential.

  1992cited by this paper
• Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.

  1992cited by this paper
• A potent specific pure antiestrogen with clinical potential.

  1991cited by this paper
• Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells.

  1990cited by this paper
• Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization.

  1990cited by this paper
• Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells.

  1989cited by this paper
• Steroidal pure antioestrogens.

  1987cited by this paper
• Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens.

  1987cited by this paper
• New biospecific adsorbents for the purification of estradiol receptor.

  1978cited by this paper
• Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen.

  1978cited by this paper
• Tamoxifen flare in advanced breast cancer.

  1978cited by this paper
• World Journal of Surgical Oncology Open Access the Use of Fulvestrant, a Parenteral Endocrine Agent, in Intestinal Obstruction Due to Metastatic Lobular Breast Carcinoma

  year unknowncited by this paper

• UBE2M forms a positive feedback loop with estrogen receptor to drive breast cancer progression and drug resistance

  2024cites this paper
• Pyrimidine–triazole‐tethered tert‐butyl‐piperazine‐carboxylate suppresses breast cancer by targeting estrogen receptor signaling and β‐catenin activation

  2024cites this paper
• Estrogen α and β Receptor Expression in the Various Regions of Resected Glioblastoma Multiforme Tumors and in an In Vitro Model

  2024cites this paper
• scPharm: Identifying Pharmacological Subpopulations of Single Cells for Precision Medicine in Cancers

  2024cites this paper
• SexAnnoDB, a knowledgebase of sex-specific regulations from multi-omics data of human cancers

  2024cites this paper
• Identification of drug responsive enhancers by predicting chromatin accessibility change from perturbed gene expression profiles

  2024cites this paper
• Catalytic Asymmetric Synthesis of Vicinally Bis(trifluoromethyl)-Substituted Molecules via Normal [3 + 2] Cycloaddition of N-2,2,2-Trifluoroethyl Benzothiophene Ketimines and β-Trifluoromethyl Enones.

  2023cites this paper
• Treatments and Management of Menopausal Symptoms: Current Status and Future Challenges

  2023cites this paper
• A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer

  2023cites this paper
• Oncogenic MORC2 in cancer development and beyond

  2023cites this paper
• Nanoparticle-based combination therapy enhances fulvestrant efficacy and overcomes tumor resistance in ER-positive breast cancer.

  2023cites this paper
• Deconstructing the contributions of heterogeneity to combination treatment of hormone sensitive breast cancer

  2023cites this paper
• Synthesis and characterization of Fulvestrant and Paclitaxel conjugates with polyamidoamine dendrimer fourth generation

  2023cites this paper
• Microgravity: New aspect for breast cancer treatment, a review

  2022cites this paper
• ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance

  2022cites this paper
• Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis

  2022cites this paper
• Benzothiophene derivatives as selective estrogen receptor covalent antagonists: Design, synthesis and anti-ERα activities.

  2021cites this paper
• 1,2,3,4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design

  2021cites this paper
• Advances in Cancer Treatment by Targeting the Neddylation Pathway

  2021cites this paper
• ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins

  2021cites this paper
• Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer.

  2021cites this paper
• MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines

  2021cites this paper
• Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells

  2020cites this paper
• Breast cancer: insights in disease and influence of drug methotrexate.

  2020cites this paper
• Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer

  2020cites this paper
• Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer.

  2020cites this paper
• Clarkson, Richard 2018. Acquired resistance of ER-positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through post-translational downregulation of c-FLIP

  2020cites this paper
• Effects of Estrogens and SERMs on Bone Metabolism: Clinical Aspects

  2020cites this paper
• The Role of Cyclin-Dependent Kinases on the Metastasis of Breast Cancer

  2020cites this paper
• Examination of the Efficacy of Fulvestrant 500 mg Targeting Estrogen Receptor-Positive Postmenopausal Metastatic Breast Cancer: Prospective Observational Study (PerSeus BC03 Study)

  2019cites this paper
• DMSO_A_190752 1419..1436

  2019influential citation
• MicroRNA Regulates Estrogen Receptor Alpha in Breast Cancer Metastasis

  2019cites this paper
• The ER Fusion System in Mouse Models: A Reversible Switch

  2019cites this paper
• Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.

  2019cites this paper
• Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha.

  2019cites this paper
• Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity

  2019cites this paper
• Polyfluorinated scaffolds in drug discovery

  2019cites this paper
• The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer

  2019cites this paper
• Estrogen receptor inhibition enhances cold-induced adipocyte beiging and glucose tolerance

  2019influential citation
• Drug metabolites and their effects on the development of adverse reactions: Revisiting Lipinski’s Rule of Five

  2018cites this paper
• Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP

  2018cites this paper
• Physalin B induces cell cycle arrest and triggers apoptosis in breast cancer cells through modulating p53-dependent apoptotic pathway.

  2018cites this paper
• Investigation into the role of HER2 receptor signalling in Hypoxia-inducible Factor Regulation in breast cancer

  2018cites this paper
• Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds

  2018cites this paper
• Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.

  2018cites this paper
• Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation

  2018cites this paper
• Potential interference of aluminum chlorohydrate with estrogen receptor signaling in breast cancer cells.

  2018cites this paper
• Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.

  2018cites this paper
• OXIDATIVE STRESS AND CARCINOGENESIS : POTENTIAL OF PHYTOCHEMICALS IN BREAST CANCER THERAPY USING MCF-7

  2017cites this paper
• Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation

  2017cites this paper
• What is known about melatonin, chemotherapy and altered gene expression in breast cancer

  2017cites this paper
• Evaluation of the antitumour activity of novel flavonoids on pre-clinical models of breast and ovarian cancer

  2017cites this paper
• Estrogen receptor inhibition enhances cold-induced adipocyte beiging and glucose sensitivity

  2017cites this paper
• Effect of tamoxifen and fulvestrant long-term treatments on ROS production and (pro/anti)-oxidant enzymes mRNA levels in a MCF-7-derived breast cancer cell line

  2016cites this paper
• Characterizing the Role of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-inducible poly-ADP-ribose Polymerase (TIPARP) in Estrogen Receptor Signalling

  2016cites this paper
• Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat.

  2016cites this paper
• Recent developments of C-4 substituted coumarin derivatives as anticancer agents.

  2016cites this paper
• Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.

  2015cites this paper
• TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer

  2015cites this paper
• Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators.

  2015cites this paper
• A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1

  2015cites this paper
• Patient pathway for breast cancer: turning points and future aspirations.

  2015cites this paper
• The estrogen receptor fusion system in mouse models: a reversible switch.

  2015cites this paper
• Transcription factors and chromatin proteins as therapeutic targets in cancer.

  2015cites this paper
• 雌激素与非小细胞肺癌关系的研究进展

  2015cites this paper
• Investigating breast cancer metastasis to brain in pre-clinical mouse models of metastasis

  2015cites this paper
• Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.

  2015cites this paper
• Development of a multi-gene PCR assay for the prediction of the response to hormone therapy in breast cancer

  2014cites this paper
• Developing three dimensional models of breast cancer

  2014cites this paper
• Organoid cultures for the analysis of cancer phenotypes.

  2014cites this paper
• Minireview: dynamic structures of nuclear hormone receptors: new promises and challenges.

  2014cites this paper
• Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer

  2014cites this paper
• Follow-Up in Inflammatory Breast Cancer

  2013cites this paper
• Endocrine therapy resistance: current status, possible mechanisms and overcoming strategies.

  2013cites this paper
• Skeletal Manifestations of Treatment of Breast Cancer on Premenopausal Women

  2013cites this paper
• Prolactin and Isplatin Combination Treatment Inhibit Tumorspheres Formation and Tumor Growth in Mice

  2013cites this paper
• UK guidance document: treatment of metastatic breast cancer.

  2012cites this paper
• Wirkung von östrogenen Substanzen auf Veränderungen des Stoffwechsels im Tiermodell der Aromatase knockout Maus

  2012cites this paper
• Hormonal Resistance in Breast Cancer: Evolving Treatment Strategies

  2012cites this paper
• The Tissue Specific Role of Estrogen and Progesterone in Human Endometrium and Mammary Gland

  2012cites this paper
• The role of uPAR in inducing a cancer stem cell-like phenotype in breast cancer and allowing cells to develop endocrine therapy resistance

  2012cites this paper
• Chromatin landscape and endocrine response in breast cancer.

  2012cites this paper
• Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells.

  2011cites this paper
• Fulvestrant for advanced male breast cancer patients: a case series.

  2011cites this paper
• Determination of Fulvestrant in Rat Plasma by LC–MS–MS: Application to a Pharmacokinetic Study

  2011cites this paper
• Estrogen Receptor-Beta Dependent Activities of Dietary Compounds in a Genetically Modified Rat Raphe Nuclei-Derived Cell Line

  2011cites this paper
• Epidermal Growth Factor and Estrogen Act by Independent Pathways to Additively Promote the Release of the Angiogenic Chemokine CXCL8 by Breast Tumor Cells 1

  2011cites this paper
• Estrogen receptor‐positive breast cancer: a multidisciplinary challenge

  2011cites this paper
• Biological mechanisms and clinical implications of endocrine resistance in breast cancer.

  2011cites this paper
• Response of Estrogen Receptor-Positive Breast Cancer Tumorspheres to Antiestrogen Treatments

  2011cites this paper
• Choosing the right cell line for breast cancer research

  2011cites this paper
• Modulators of androgen and estrogen receptor activity.

  2010cites this paper
• Acquired resistance of ER-positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through post-translational

  year unknowncites this paper